AI Article Synopsis
- * A case study discusses a 57-year-old Japanese man whose alectinib treatment had to be stopped twice due to hepatotoxicity after a total of 143 days on the drug.
- * After switching to lorlatinib, the patient was able to continue treatment for over 4 months without severe side effects, suggesting lorlatinib is a viable option for those who experience liver issues from alectinib.
Article Abstract
Alectinib is a key drug for treating ()-positive non-small-cell lung cancer (NSCLC). Alectinib-induced hepatotoxicity is less common than that through other ALK inhibitors, such as crizotinib or ceritinib. Herein, we describe a case of -positive adenocarcinoma successfully treated with lorlatinib after developing alectinib-induced hepatotoxicity. A 57-year-old Japanese man received alectinib as first-line therapy for -positive NSCLC. After 79 days, alectinib was discontinued because of hepatotoxicity and later restarted at 150 mg/day, inducing hepatotoxicity again after 64 days. Switching to lorlatinib treatment (continued for >4 months) caused no severe adverse effects. Hence, lorlatinib may be useful for patients experiencing alectinib-induced hepatotoxicity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983536 | PMC |
| http://dx.doi.org/10.1159/000513624 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hyperbilirubinemia in a Patient Receiving Alectinib for Anaplastic Lymphoma Kinase Positive Non-Small-Cell Lung Cancer: A Histological Features.
Onco Targets Ther
December 2024
Department of Infectious Disease, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Background: Alectinib is a second generation of anaplastic lymphoma kinase (ALK) inhibitor that has been approved for the treatment of advanced non-small-cell lung cancer (NSCLC) with ALK rearrangements. Hepatotoxicity is the most common adverse drug reaction. However, there is currently no published report on the pathologic findings of alectinib-induced hyperbilirubinemia.
View Article and Find Full Text PDFSuccessful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report.
Case Rep Oncol
March 2021
Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan.
Article Synopsis
- * A case study discusses a 57-year-old Japanese man whose alectinib treatment had to be stopped twice due to hepatotoxicity after a total of 143 days on the drug.
- * After switching to lorlatinib, the patient was able to continue treatment for over 4 months without severe side effects, suggesting lorlatinib is a viable option for those who experience liver issues from alectinib.
A cascade dual-targeted nanocarrier for enhanced alectinib delivery to ALK-positive lung cancer.
Biomater Sci
November 2020
Division of Thoracic Surgery, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510080, P. R. China.
Alectinib is a highly efficacious inhibitor for the treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in the clinic; however, serious adverse events (AEs) occurred in 44.0% of patients. Herein, we explored magnetic/TAT dual-targeted nanocarriers as delivery systems for alectinib.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!